Germany-based Boehringer Ingelheim has received approval from the US Food and Drug Administration for the use of its Spiriva HandiHaler (tiotropium bromide inhalation powder) as a long-term, once-daily maintenance treatment for bronchospasm associated with chronic obstructive pulmonary disease. The product will be co-promoted by US drug major Pfizer under an agreement signed by the two firms in 2001 (Marketletter April 23, 2001).
Clinical evidence
In clinical trials, Spiriva demonstrated significant bronchodilation that was sustained over the duration of the studies. The agent has also demonstrated significant improvements in lung function over Atrovent (ipratropium bromide), a current first-line therapy for COPD, which were maintained over one year. Clinical studies, both ongoing and completed, include more than 9,400 patients, noted BI.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze